Vasiliki Leventaki

Dr. Vasiliki Leventaki

Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2019 in Cancers
Verified
Journal Article
Open access
PDF file
VAvasileios atsaves
vasileios atsaves
VLVasiliki Leventaki
Vasiliki Leventaki
George RassidakisGeorge Rassidakis
George Rassidakis
FCFrancois-xavier Claret
Francois-xavier Claret
Immune check point blockade therapy has revolutionized the standard of cancer treatment and is credited with producing remarkable tumor remissions and increase in overall survival. This unprecedented clinical success however is feasible for a limited number of cancer patients due to resistance occurring before or during a course of immunotherapy, which is often associated with activation of oncogenic signaling pathways, co-inhibitory checkpoints upregulation or expansion of immunosuppressive regulatory T-cells (Tregs) in the tumor microenviroment (TME). Targeted therapy aiming to inactivate a signaling pathway such as the Mitogen Activated Protein Kinases (MAPKs) has recently received a lot of attention due to emerging data from preclinical studies indicating synergy with immune checkpoint blockade therapy. The dimeric transcription factor complex Activator Protein-1 (AP-1) is a group of proteins involved in a wide array of cell processes and a critical regulator of nuclear gene expression during T-cell activation. It is also one of the downstream targets of the MAPK signaling cascade. In this review, we will attempt to unravel the roles of AP-1 in the regulation of anti-tumor immune responses, with a focus on the regulation of immune checkpoints and Tregs, seeking to extract useful insights for more efficacious immunotherapy.

28 February 2019 in Haematologica
Verified
Journal Article
Closed access
PDF file
DGDylan Graetz
Dylan Graetz
KCKristine R. Crews
Kristine R. Crews
EAElizabeth M. Azzato
Elizabeth M. Azzato
RSRavi K. Singh
Ravi K. Singh
SRSusana Raimondi
Susana Raimondi
VLVasiliki Leventaki
Vasiliki Leventaki

1 April 2022 in Cancer Genetics
Verified
Journal Article
Closed access
LMLauren J. Miller
Lauren J. Miller
VLVasiliki Leventaki
Vasiliki Leventaki
PHPaul D. Harker-Murray
Paul D. Harker-Murray
HDHolli M. Drendel
Holli M. Drendel
KBKathleen M. Bone
Kathleen M. Bone

17 August 2022 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
SLSam Lyvannak
Sam Lyvannak
KSKorb Sreynich
Korb Sreynich
SHSing Heng
Sing Heng
MTMiliya Thyl
Miliya Thyl
ACArjun Chandna
Arjun Chandna
BWBenjamin Watkins
Benjamin Watkins
: Leishmaniasis is considered a neglected tropical disease that is commonly found in Asia, Africa, South America, and Mediterranean countries. Visceral leishmaniasis (VL) is the most severe form of the disease and is almost universally fatal if left untreated. The symptoms of VL overlap with many infectious diseases, malignancies, and other blood disorders. The most common findings include fever, cytopenias, and splenomegaly. Given the nonspecific symptoms, the diagnosis requires detailed laboratory investigations, including bone marrow examination, that can be challenging in low- and middle-income countries. Diagnostic limitations likely lead to the underdiagnosis or delay in diagnosis of VL. We describe, to our knowledge, the first case report of VL in Cambodia in a child presenting with fever, anemia, and thrombocytopenia. The diagnosis required a liver biopsy and multiple bone marrow biopsies to visualize intracellular Leishmania spp. Our case illustrates the diagnostic challenges and the importance of timely diagnosis. This case also highlights the need for heightened awareness of the diagnostic findings of VL and improved reporting of tropical diseases.

14 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
DCDimitrios Chioureas
Dimitrios Chioureas
JBJanina Beck
Janina Beck
GBGeorge Baltatzis
George Baltatzis
IVIoulia Vardaki
Ioulia Vardaki
PFPedro Fonseca
Pedro Fonseca
Theocharis PanaretakisTheocharis Panaretakis
Theocharis Panaretakis
The oncogenic pathways activated by the NPM-ALK chimeric kinase of ALK+ anaplastic large cell lymphoma (ALCL) are well characterized; however, the potential interactions of ALK signaling with the microenvironment are not yet known. Here we report that ALK+ ALCL-derived exosomes contain critical components of ALK signaling as well as CD30, and that exosome uptake by lymphoid cells led to increased proliferation and expression of critical antiapoptotic proteins by the recipient cells. The bone marrow fibroblasts highly uptake ALK+ ALCL-derived exosomes and acquire a cancer-associated fibroblast (CAF) phenotype. Moreover, exosome-mediated activation of stromal cells altered the cytokine profile of the microenvironment. These interactions may contribute to tumor aggressiveness and possibly resistance to treatment.